Dev

PHOSPHATASE PROTEIN 2A AS A THERAPEUTIC DIAL FOR THE DEVELOPMENT OF NEW PHARMACIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Investments < €500k Spain 2016    

PERIPHERAL INFLAMMATION AS A RISK FACTOR IN THE PATHOLOGY OF ALZHEIMER’S DISEASE: NEW DIAGNOSTIC TOOLS AND THERAPEUTIC DIALOGS Investments < €500k Spain 2016    

STUDY OF BIOMARKERS IN THE CONTINUOUS PATHOLOGICAL EXISTING BETWEEN LATERAL AMIOTROPHIC SCLEROSIS (ELA) AND LOBULAR DEVELOPMENT FRONTOTEMPORAL (DLFT) – I Investments < €500k Spain 2016    

GENETIC-MOLECULAR BASES OF SPINOCEREBELOSE ATAXIES: IDENTIFICATION AND CHARACTERIZATION OF THE CAUSE OF DEFINITION OF SPINOCEREBELOSA ATAXIA 37 (SCA37). Investments < €500k Spain 2016    

CERVICAL-CEREBRAL ATEROSCLEROSIS, ICTUS AND COGNITIVE DETERIORATION INCIDENTS IN THE POPULATION COHORT ASIA Investments < €500k Spain 2016    

EXPRESSION PROFILES OF GLUCOCEREBROSIDASA MRNA AND ITS REGULATORY GENES IN BRAIN AND PERIPHERAL BLOOD: IDENTIFICATION OF BIOLOGICAL SIGNALS FOR DEMENTIA WITH LEWY BODIES. Investments < €500k Spain 2016    

IMMUNE RESPONSE ADAPTATIVE IN PARKINSON DISEASE INDUCED BY ALPHA-SINUCLEINE PROTEOFINS PRESENT IN THE LEWY BODIES: DIAGNOSTIC AND THERAPEUTIC APPLICATION Investments < €500k Spain 2016    

INTERPLAY OF AMYLOID AND ISCHEMIA AND THEIR INFLUENCE ON BLOOD-BRAIN BARRIER, AMYLOID TRANSPORTATION SYSTEMS AND NEURODEGENERATION IN CEREBRAL AMYLOID ANGIOPATHY (CAA) Investments < €500k Spain 2016    

PROGRESSION OF SMALL CEREBRAL VASCULAR DISEASE: RISK FACTORS, IMPLICATED MECHANISMS AND CLINICAL CONSEQUENCES. Investments < €500k Spain 2016    

ROLE OF NEUROMELANIN AND ALPHA-SINUCLEINE IN THE START AND EXTENSION OF PARKINSON DISEASE: DIAGNOSTIC AND THERAPEUTIC POTENTIAL IN NEW PRE-CLINICAL MODELS Investments < €500k Spain 2016